Table 4

Univariable and multivariable models of the impact of disease activity states on specific organ damage accrual

UnivariableMultivariable*
OR (95% CI)OR (95% CI)
Ophthalmological
 Remission off-treatment0.88 (0.77 to 1.01) 0.84 (0.72 to 0.97)
 Remission on-treatment 0.79 (0.64 to 0.96) 0.72 (0.59 to 0.88)
 LDA-TC 0.71 (0.52 to 0.96) 0.69 (0.50 to 0.94)
 mLLDAS0.91 (0.71 to 1.17)0.88 (0.69 to 1.13)
Neuropsychiatric
 Remission off-treatment 0.80 (0.68 to 0.99) 0.85 (0.73 to 0.99)
 Remission on-treatment 0.55 (0.42 to 0.72) 0.66 (0.53 to 0.82)
 LDA-TC0.75 (0.51 to 1.09)0.76 (0.54 to 1.05)
 mLLDAS 0.63 (0.40 to 1.00)0.75 (0.53 to 1.05)
Renal
 Remission off-treatment 0.52 (0.39 to 0.67) 0.71 (0.54 to 0.92)
 Remission on-treatment 0.43 (0.31 to 0.61) 0.54 (0.38 to 0.78)
 LDA-TC 0.12 (0.03 to 0.51) 0.27 (0.10 to 0.77)
 mLLDAS 0.43 (0.22 to 0.87)0.65 (0.36 to 1.17)
Lung
 Remission off-treatment 0.59 (0.44 to 0.80) 0.71 (0.53 to 0.95)
 Remission on-treatment 0.77 (0.59 to 0.99)0.85 (0.68 to 1.07)
 LDA-TC 0.52 (0.29 to 0.92)0.63 (0.40 to 1.01)
 mLLDAS0.58 (0.34 to 1.00)0.68 (0.43 to 1.07)
Cardiovascular
 Remission off-treatment 0.79 (0.64 to 0.99) 0.73 (0.58 to 0.92)
 Remission on-treatment 0.70 (0.53 to 0.93) 0.66 (0.51 to 0.92)
 LDA-TC0.97 (0.73 to 1.30)0.89 (0.68 to 1.17)
 mLLDAS0.64 (0.36 to 1.10)0.62 (0.36 to 1.05)
Peripheral vascular
 Remission off-treatment0.89 (0.69 to 1.15)0.97 (0.75 to 1.25)
 Remission on-treatment 0.66 (0.45 to 0.98)0.75 (0.52 to 1.08)
 LDA-TC 0.03 (0.00 to 0.83) 0.06 (0.00 to 0.87)
 mLLDAS1.07 (0.68 to 1.67)1.16 (0.78 to 1.72)
Gastrointestinal
 Remission off-treatment1.02 (0.79 to 1.33)1.05 (0.81 to 1.37)
 Remission on-treatment1.12 (0.81 to 1.56)1.17 (0.86 to 1.59)
 LDA-TC0.99 (0.58 to 1.70)1.01 (0.60 to 1.69)
 mLLDAS1.14 (0.66 to 1.96)1.27 (0.77 to 2.09)
Musculoskeletal
 Remission off-treatment 0.89 (0.83 to 0.96) 0.70 (0.58 to 0.84)
 Remission on-treatment0.93 (0.84 to 1.02) 0.77 (0.62 to 0.94)
 LDA-TC0.96 (0.85 to 1.08)0.82 (0.62 to 1.09)
 mLLDAS1.04 (0.92 to 1.17)0.92 (0.69 to 1.22)
Skin
 Remission off-treatment 0.66 (0.52 to 0.85) 0.69 (0.53 to 0.90)
 Remission on-treatment 0.47 (0.32 to 0.70) 0.52 (0.36 to 0.75)
 LDA-TC1.07 (0.85 to 1.36)1.06 (0.82 to 1.37)
 mLLDAS0.71 (0.44 to 1.13)0.72 (0.46 to 1.12)
Gonadal
 Remission off-treatment 0.43 (0.22 to 0.84) 0.48 (0.25 to 0.94)
 Remission on-treatment0.68 (0.39 to 1.19)0.77 (0.45 to 1.32)
 LDA-TC1.07 (0.63 to 1.83)1.12 (0.66 to 1.89)
 mLLDAS0.48 (0.11 to 2.09)0.65 (0.18 to 2.30)
Diabetes
 Remission off-treatment0.73 (0.50 to 1.05)0.73 (0.51 to 1.05)
 Remission on-treatment0.60 (0.35 to 1.02)0.61 (0.37 to 1.02)
 LDA-TC0.67 (0.24 to 1.83)0.66 (0.25 to 1.74)
 mLLDAS 0.28 (0.11 to 0.69) 0.32 (0.16 to 0.64)
Cancer
 Remission off-treatment1.24 (1.00 to 1.53)1.10 (0.87 to 1.40)
 Remission on-treatment1.36 (1.05 to 1.76)1.19 (0.90 to 1.56)
 LDA-TC1.10 (0.71 to 1.70)1.03 (0.65 to 1.63)
 mLLDAS1.28 (0.86 to 1.89)1.17 (0.79 to 1.73)
  • *Adjusted for included sex, age at diagnosis, race/ethnicity, education, baseline disease duration, follow-up time the highest-ever glucocorticoid dose prior to cohort entry, antimalarials and the score of the same organ damage.

  • LDA-TC, low disease activity Toronto cohort; mLLDAS, modified lupus low disease activity state.